Objective: Cytokines and adhesion molecules have a decisive role in the development of early inflammatory response as well as the late sequelae of sepsis. Because L-selectin-deficient mice are protected from lethal endotoxemia, blockade of L-selectin may provide a useful therapeutic option in human sepsis. Heparin has immunomodulatory properties and effectively inhibits L-and P-selectin binding in vitro. We therefore investigated whether clinically applied doses of unfractionated or low-molecular-weight heparin affect early inflammatory response in human endotoxemia.
S epsis results from a generalized inflammatory and procoagulant response to infectious agents. Cytokines and adhesion molecules, such as selectins, are of utmost importance for the development of early symptoms as well as the late sequelae of sepsis (1); for example, Lselectin-deficient mice are protected from lethal endotoxemia (2) . Thus, blockade of L-selectin may provide a useful therapeutic option in human sepsis.
Heparin is widely known as an anticoagulant and antithrombotic agent. But beyond its well-understood anticoagulant activity, heparin is able to influence immunologic responses (3) and effectively inhibits L-and P-selectin-mediated adhe-sion in vitro at clinically relevant concentrations (4) . This has been confirmed by various in vitro and animal models (3, (5) (6) (7) .
Results from several small clinical trials indicate antiinflammatory properties of heparin in human inflammatory and allergic diseases, as reviewed recently (8, 9) . Thus, heparin may exert some of its putative antiinflammatory functions via blockade of selectin/ligand interactions.
Interestingly, recombinant human activated protein C, an endogenous anticoagulant, decreases mortality in sepsis, which is accompanied by a decrease in D-dimer and interleukin (IL)-6 levels (10) . Although its mechanism of action in sepsis is not entirely clear, recent in vitro data also demonstrate that recombinant human activated protein C down-regulates endothelial adhesion molecule expression, which could contribute to the efficacy of recombinant human activated protein C in sepsis (11) .
Of note, a possible interaction between heparin and recombinant human activated protein C is going to be tested in septic patients. In view of this oncoming clinical trial and the proposed antiinflam-matory effects of heparin in different clinical settings, it is of interest to study intrinsic antiinflammatory properties of heparin in human endotoxemia.
We hypothesized that heparin may inhibit inflammation by blockade of L-and P-selectin interaction with their ligands as observed in vitro.
In the current study, we investigated whether unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) affects early inflammatory responses, i.e., regulation of adhesion molecules, cytokines and activation of leukocytes, endothelial cells and platelets, in low-grade human endotoxemia.
METHODS

Study Design and Study Subjects.
The study protocol was approved by the Ethics Committee of the Vienna University.
All participants gave written informed consent before entering the study. The study was a randomized, double-blinded, placebocontrolled study in three parallel groups of 30 healthy male subjects with a mean age of 28 Ϯ 6 yrs (n ϭ 10 per group).
Basic examination included medical history, physical examination, laboratory variables, and virological and drug screening. Additionally, study subjects were tested for hereditary thrombophilia. Exclusion criteria were previous exposure to heparin and recent intake of medication.
Study Protocol. The detailed study procedures have been outlined previously (12) .
Lipopolysaccharide (LPS) in a dose of 2 to 4 ng/kg has repeatedly and safely been used in clinical studies (13) . In our previous studies in healthy male subjects (14, 15) , 2 ng/kg seemed to be better tolerated than 4 ng/kg without eliminating responses of the coagulation system and hematologic phenomena.
Thus, a bolus of LPS 2 ng/kg (national reference endotoxin, Escherichia coli; USP Convention, Rockville, MD) was infused in all subjects. Ten minutes after infusion of LPS, individuals from the UFH group received 80 IU/kg heparin (Heparin Immuno, Immuno AG, Vienna, Austria) followed by a continuous infusion of 18 IU/kg/hr for 6 hrs. Subjects allocated to the LMWH group received dalteparin (Fragmin, Pharmacia & Upjohn, Vienna, Austria) 40 IU/kg followed by a continuous infusion of 15 IU/kg/hr for 6 hrs. Identical volumes of saline solution were infused in the placebo group.
Blood Sampling. Blood samples were collected into citrated or EDTA anticoagulated evacuated tubes (Vacutainer, Becton Dickinson, Mountain View, CA) by venipuncture half an hour before, and 1, 2, 3, 4, 6, and 24 hrs after, LPS infusion. Plasma was obtained by centrifugation at 3000 ϫ g (15 mins at 4°C) and stored in 0.5-mL aliquots at Ϫ80°C until batch analysis.
In Vitro Incubation Experiments. In vitro experiments were performed to investigate whether heparins directly inhibit LPS-induced down-regulation of L-selectin.
Whole blood was incubated with LPS (50 pg/mL or 1 ng/mL) in the presence or absence of UFH or dalteparin (2 units/mL) for 2 hrs. Flow cytometric analysis was performed as described below.
Blood Cell Counts. Differential blood counts were performed with a cell counter (Sysmex, Kobe, Japan).
Flow Cytometric Analyses. Platelet-leukocyte aggregates were evaluated by measuring CD41 ϩ neutrophils as described previously (16) . CD11b and L-selectin expression were quantified by flow cytometry as well (FACS-Calibur, Becton Dickinson) (17) . The CD41 and L-selectin antibodies were fluoro-isothiocyanate labeled (Immunotech, Marseille, France) and the CD11b antibody was phycoerythrin labeled (Becton Dickinson, Vienna, Austria). Data are presented as mean fluorescence intensity (MFI).
Analyses of Soluble Variables. Plasma levels of circulating (c)P-selectin, cE-selectin, tumor necrosis factor (TNF)-␣, IL-6, and IL-8 were measured by using enzyme-linked immunosorbent assay (R&D Systems, Minneap-olis, MN) (18) . C-reactive protein (CRP) values were determined by nephelometry (Tinaquant CRP, Boehringer Mannheim/Hitachi, Germany). Antithrombin levels (STA antithrombin, Diagnostica Stago, Asnieres, France) were determined on an STA analyzer (Stago, Asnieres, France).
Testing for Heparin-Induced Thrombocytopenia. Tests for heparin-induced thrombocytopenia were performed in all study subjects before, and 7 days after, LPS challenge.
Heparin-induced antibodies were determined by using enzyme-linked immunosorbent assay techniques, which detect immunoglobulin G/immunoglobulin M/immunoglobulin A antibodies (Asserachrom HPIA, Diagnostica Stago; GTI-HAT, Millwaukee, WI) and the functional heparin-induced platelet activation test as described in detail elsewhere (19) .
Data Analysis. Data are expressed as mean and 95% confidence interval if not otherwise specified. Two-way analysis of variance and the LSD test were used for post hoc comparisons (Statistica Software, Tulsa, OK). A two-tailed p value Յ.05 was considered significant.
RESULTS
There was no difference of baseline variables between subjects treated with UFH, LMWH, or placebo ( Table 1) .
The anticoagulant potency of UFH and LMWH was reported previously (12) by prevention of F 1ϩ2 generation (p Ͻ .001 UFH vs. placebo, p Ͻ .01 LMWH vs. placebo). Antithrombin values decreased by 4.8% (0.9%-8.6%) in the placebo group, by 9.1% (4.6%-13.7%) in the UFH, and by 0.1% (Ϫ5.0%-4.8%) in the LMWH group, 6 hrs after LPS infusion (p Ͻ .05 between groups) (12) .
Testing for Heparin-Induced Thrombocytopenia Antibodies. One subject tested positive for heparin-induced thrombocytopenia antibodies before and after the trial but did not exhibit thrombocytopenia, one tested positive in the Asserachrom assay on day 7, but was negative in GTI-HAT testing, and did not develop thrombocytopenia after heparin treatment. All other study participants tested negative.
L-Selectin, CD11b Expression, and Blood Counts. In line with previous results (17) , neutrophil counts decreased sharply 70 mins after LPS infusion and increased significantly above baseline from 2 to 8 hrs (maximal value 8.6 [7.1-10.0] ϫ 10 9 /L in the placebo group, 8.0 [6.5-9.6] ϫ 10 9 /L in the LMWH group, and 8.7 [7.9 -9.5] ϫ 10 9 /L in the heparin group). Platelet counts decreased by a maximum of 13% to 15% in all treatment groups after 112 mins (p Ͻ .001 vs. baseline, data not shown). Changes in neutrophil and platelet counts were not modified by any treatment (p ϭ not significant between groups).
In contrast, LPS-induced lymphocytopenia was significantly less pronounced in the UFH group than in the placebo group during the first 6 hrs (p Ͻ .05 for all time points; Fig. 1 ).
As expected (17), LPS infusion increased CD11b expression by approximately 400% but decreased L-selectin by Ϫ32% (Ϫ55% to Ϫ8%) in the placebo arm after 6 hrs. Interestingly, LMWH and in particular UFH decreased L-selectin down-modulation at 6 UFH, unfractionated heparin; LMWH, low-molecular-weight heparin; TNF, tumor necrosis factor; CRP, C-reactive protein; IL, interleukin; FACS, fluorescence-activated cell sorter; MFI, mean fluorescence intensity.
a Number of subjects with IL-8 levels above detection limit (Ͼ10 pg/mL). Data are presented as mean (95% confidence interval) if not otherwise specified.
hrs as compared with placebo: Ϫ5% (Ϫ23% to 11%) in the UFH and Ϫ24% (Ϫ38% to Ϫ10%) in the LMWH group (p Ͻ .028 for percentage change UFH vs. placebo; Fig. 1 ). The percentage of L-selectinpositive lymphocytes increased slightly from 73% (69%-76%) to a maximum of 82% (80%-84%) after 6 hrs and returned to basal values at 24 hrs (71% [67%-75%]) (p Ͻ .01 vs. baseline). Similarly, the MFI increased from 132 (121-143) to a peak value of 165 (152-178) at 6 hrs and afterward decreased to 137 (127-146) at 24 hrs (p Ͻ .01 vs. baseline) There were no differences between treatment groups (p ϭ not significant).
cE-Selectin, cP-Selectin, Platelet-Leukocyte Aggregates. Plasma levels of the endothelial activation marker cEselectin increased by approximately 500% and levels of the platelet activation marker cP-selectin by 50% to 66% 6 hrs after LPS infusion in all groups (Fig. 2) . Similarly, platelet-leukocyte aggregates, as measured by CD41 ϩ neutrophils, increased in all groups (p Ͼ .05 between treatments, data not shown).
TNF-␣, IL-6, IL-8, and CRP. After LPS infusion, TNF-␣ levels increased Ͼ350fold in the LMWH and placebo groups, but only 150-fold in the UFH group (p ϭ .07 UFH vs. LMWH group). IL-6, IL-8 ( Fig. 2) , and CRP levels were not different between treatment groups; CRP levels: 4.5 (2.8 -6.1) mg/dL in the placebo group; 3.0 (1.8 -4.0) mg/dL in the UFH group; and 3.9 (3.0 -4.8) mg/dL in the LMWH group.
In Vitro Experiments. L-selectin expression on lymphocytes ranged from 66% to 83% in vitro. LPS did not reduce L-selectin MFI relative to NaCl incubation or vs. baseline (basal MFI 94 vs. 92 after 1 ng/mL LPS). Incubation with LPS dose dependently down-regulated Lselectin expression on neutrophils from 184 (161-206) to 74 (62-85) MFI (Fig. 3) . Neither UFH nor LMWH inhibited direct LPS-induced down-regulation of Lselectin (Fig. 3) . In contrast to neutrophils, L-selectin expression on lymphocytes was not regulated by LPS incubation.
DISCUSSION
Because heparins have been proposed to exert antiadhesive and antiinflammatory effects (9), we set out to investigate whether UFH or LMWH has intrinsic immunomodulatory properties in experimental human endotoxemia.
Interestingly, UFH and, to a lesser extent, LMWH decreased L-selectin down-modulation as compared with placebo. Because cross-linking of L-selectin by ligands leads to its down-regulation, reduced down-regulation may reflect blockade of L-selectin through heparin (20) . This is in line with in vitro data showing that UFH and, to a lesser extent, LMWH effectively inhibited L-and P-selectin binding at therapeutically relevant concentrations (4) . The observation that UFH attenuated the decrease in lymphocyte counts further supports this concept, because L-selectin has a pivotal role in lymphocyte homing (21) . Notably, Lselectin-deficient mice have defective lymphocyte homing but do not exhibit neutrophilia (2) , and neutrophilia was not exaggerated in our UFH-treated subjects. Because lymphocytopenia is a cardinal feature of severe sepsis (1), it will be interesting to investigate the effects of heparin on lymphocyte counts in septic patients.
The moderate effects of UFH merit short discussion. Several pathways of Lselectin down-regulation exist. L-selectin down-regulation can result from crosslinking by ligands, a prerequisite for transendothelial migration of neutrophils. Alternatively, activation of neutro- phils by LPS or other stimuli leads to activation-dependent L-selectin downregulation (20) . As shown in our in vitro experiments, this cannot be blocked by UFH, indicating that heparin should work by inhibition of ligand-induced Lselectin down-regulation in vivo.
In contrast to neutrophils, LPS did not decrease L-selectin levels on lymphocytes in vitro. Likewise, there was no downregulation of L-selectin in vivo. The small increase in the percentage of L-selectinpositive lymphocytes and MFI probably reflects the higher expression level of Lselectin on those lymphocytes remaining in the circulation or those recirculating during LPS-induced lymphocytopenia. Because LPS infusion leads to considerable changes in lymphocyte subsets in vivo (22) , and because lymphocytes display variable degrees of L-selectin expression (23) , any change in L-selectin on lymphocytes likely reflects changing leukocyte populations in vivo, rather than true LPS-induced modulation of Lselectin expression.
Lymphocyte homing is not solely mediated through L-selectin, because activated platelets bind circulating lymphocytes and enhance tethering of lymphocytes and lymphocyte rolling (21) . Because we observed no effect of UFH or LMWH on platelet activation as measured by P-selectin release into circulation or platelet-leukocyte aggregates, part of the lymphocytopenia could also result from platelet-mediated lymphocyte tethering. Whereas these results could potentially reflect a true effect of UFH via blockade of L-selectin interaction with its ligands, UFH exhibited no antiinflammatory properties as reflected by endothelial activation markers such as E-selectin or cytokine production.
The proinflammatory cytokines TNF-␣, IL-6, and IL-8 are induced in early response to infectious agents (1). We observed trendwise lower TNF-␣ levels in the UFH as compared with the LMWH group (p ϭ .07). Yet, soluble Eselectin levels, which depend on TNF-␣ generation in endotoxemia (24), were similar in all groups. Thus, the clinical relevance of a (nonsignificant) 150-fold vs. 350-fold increase in TNF-␣ generation remains unclear in view of similar endothelial activation.
Factor Xa elicits synthesis and release of IL-6 and IL-8 from endothelium, whereas thrombin induces IL-6 and IL-8 production by endothelial cells and release from monocytes (25) . We demonstrated no inhibition of IL-6 and IL-8 release by UFH or LMWH. This is in line with a recently published study showing that tissue-factor pathway inhibitor, a direct inhibitor of Factor Xa, did not mitigate IL-8 and CRP release by LPS in humans (26) . Thus, we confirm that compared with the overwhelming effect of LPS on cytokine release, the contribu-tion of Factor Xa to cytokine production is negligible in low-grade endotoxemia.
However, antithrombin itself binds to glycosaminoglycans on endothelial membranes (27, 28) . This may limit an interaction between endothelial cells and neutrophils, reduce platelet aggregation, and decrease cytokine production. Interestingly, this effect seems to be abolished by heparin, probably through competitive inhibition of antithrombin binding to glycosaminoglycans (29) . Thus, antiinflammatory actions of heparin and antithrombin could be attenuated through competitive inhibition of each other. Intriguingly, antithrombin substitution seemed to have beneficial effects in severe sepsis only without concomitant administration of heparin (30) .
However, our study has one evident limitation. There are relevant differences between clinical septic shock and experimental endotoxemia, because LPS is a noninfectious mediator, with self-limited consequences in our setting and does not induce organ failure.
In conclusion, heparin displayed little antiinflammatory actions in low-grade human endotoxemia as measured by cytokine levels, endothelial, leukocyte, or platelet activation markers. Of note, however, UFH reduced L-selectin downregulation and lymphocytopenia, which could represent a novel mechanism of action. Thus, it will be interesting to study the influence of UFH on lymphocyte homing in adequate animal models. If UFH shows an inhibitory effect on lymphocyte homing in such models, it may deserve further investigation as an immune modulatory drug in L-selectindependent diseases. 
